13.07.2013 Views

96. Jahrestagung der Deutschen Gesellschaft für Pathologie e. V ...

96. Jahrestagung der Deutschen Gesellschaft für Pathologie e. V ...

96. Jahrestagung der Deutschen Gesellschaft für Pathologie e. V ...

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

DO-094<br />

Do activated fibroblasts influence epi<strong>der</strong>mal growth factor receptor<br />

(EGFR) inhibitor sensitivity in oral squamous cell carcinoma<br />

cells (OSCC)?<br />

P . Richter 1 , N . Neumann 2 , J . Schulte 3 , K . Schult 1 , S . Weisheit 4 , M . Franz 5 ,<br />

O . Guntinas-Lichius 6 , C . Liebmann 4 , I . Petersen 1 , A . Berndt 1<br />

1 Jena University Hospital, Institute of Pathology, Jena, 2 University Hospital<br />

Zurich, Institute of Surgical Pathology, Zurich, Switzerland, 3 Ludwig-Maximilian-University,<br />

Munich, Großha<strong>der</strong>n Medical Center/Department of Cardiac<br />

Surgery, München, 4 Friedrich Schiller University Jena, Institute of Biochemistry<br />

and Biophysics, Jena, 5 Jena University Hospital, Clinic for Internal<br />

Medicine I, Jena, 6 Jena University Hospital, Department of Otorhinolaryngology,<br />

Jena<br />

Aims. Although EGFR is involved in development of OSCC and EGFRinhibitor<br />

sensitivity could be shown in OSCC cell lines, a therapeutic<br />

benefit of an EGFR-inhibitor therapy can be observed only in a minority<br />

of patients. It was suggested that the carcinoma microenvironment have<br />

modulating effects on inhibitor sensitivity in vivo. One possible hypothesis<br />

is that carcinoma associated fibroblasts induce phenotype changes<br />

such as epithelial-mesenchymal transition (EMT) which are accompanied<br />

by alterations in EGFR signalling. Thus, the study was aimed at investigating<br />

the influence of growth factor activated fibroblasts on EGFRinhibitor<br />

sensitivity of OSCC in vitro applying Gefitinib.<br />

Methods. “Activated” fibroblasts were generated by stimulation of<br />

hTERT-BJ1 fibroblasts with TGFbeta1, PDGFAB, aFGF, and TGFbeta1/<br />

aFGF, respectively. They were characterized with regard to proliferation,<br />

expression of fibroblast markers, activation of EGFR signalling, and<br />

the capability to induce OSCC cell invasion as well as their Gefitinib<br />

sensitivity using immunohistochemistry, western blotting, rtRT-PCR,<br />

MTT test and Boyden chamber assay. Furthermore, Gefitinib sensitivity<br />

was evaluated in different OSCC cell lines by MTT test. The impact of<br />

TGFbeta1 and TGFbeta1/aFGF activated fibroblasts on EGFR inhibitor<br />

sensitivity was assessed by pre-culturing of OSCC cells in fibroblast conditioned<br />

media.<br />

Results. In vitro activated fibroblasts showed a strong upregulation of<br />

ASMA and fibronectin due to stimulation with TGFbeta1. PDGFAB stimulation<br />

induced proliferation with up-regulation of EGFR and pAKT.<br />

aFGF and TGFbeta/aFGF stimulation resulted in an intermediate phenotype.<br />

TGFbeta1 stimulated fibroblasts exhibited the highest capability<br />

to induce invasion in the OSCC cell line PE/CA-PJ15 with upregulation of<br />

N-cadherin. Interestingly, activated fibroblasts differed in their Gefitinib<br />

sensitivity (TGFbeta-stim.=”low” and PDGFAB stim.=”high”). OSCC<br />

cell lines tested so far show a different Gefitinib sensitivity. Furthermore,<br />

pre-culturing in fibroblast conditioned medium leads to a partial reversibility<br />

of the Gefitinib effect.<br />

Conclusions. Results indicate that: 1) EGFR inhibition by Gefitinib<br />

affects OSCC cells as well as activated stromal fibroblasts, 2) the different<br />

Gefitinib sensitivity of fibroblast phenotypes may lead to a selective<br />

accumulation of myofibroblasts during treatment, and 3) OSCC cell sensitivity<br />

is modulated by stromal fibroblasts.<br />

DO-095<br />

Evaluation of post-transplant lymphoproliferative diseases<br />

(PTLD) with manifestation in the oral cavity<br />

C . Tiede1 , B . Maecker-Kolhoff 2 , H . Kreipe1 , K . Hussein1 1 2 Hannover Medical School, Institute of Pathology, Hannover, Hannover<br />

Medical School, Hannover<br />

Aims. Inspection of the oral cavity can be easily performed in transplanted<br />

patients with an oral tumour mass and suspected Epstein-Barr virus<br />

(EBV)-associated post-transplant lymphoproliferative disease (PTLD).<br />

We aimed to evaluate the main sites of manifestation and the morphological<br />

subtypes of PTLD in the oral cavity.<br />

Methods. Evaluation of histomorphology and clinical data on early lesion,<br />

polymorphic, and monomorphic PTLD. Total cohort of 212 patients<br />

(median age 9 years, range 0.5–70 years, 57% males/43%females, 75.5%<br />

children/24.5% adults).<br />

Results. Oral cavity PTLD manifestation was found in 61/212 patients<br />

(29%): 42/61 early lesion PTLD (20%), 12/61 polymorphic PTLD (6%)<br />

and 7/61 monomorphic PTLD (3%). Tonsils were the most frequent site<br />

of manifestation (n=57/61, 93%) including early lesion PTLD (n=42/57,<br />

74%), polymorphic PTLD (n=12/57, 21%) and monomorphic B cell PTLD<br />

(n=3/57, 5%). Other localisations were gingiva (n=2/61, 3%; EBV+ plasmocytomas),<br />

maxillary bone (n=1/61, 1.5%; EBV+ plasmocytomas) and<br />

larynx (n=1/61, 1.5%; EBV-T-cell PTLD).<br />

Conclusions. Tonsils are the main site of PTLD manifestation in the oral<br />

cavity and comprise mainly benign early lesion PTLD and polymorphic<br />

PTLD. Oral cavity monomorphic PTLD is rare and is located outside of<br />

the tonsils in a consi<strong>der</strong>able proportion (n=4/7, 57%) of cases.<br />

DO-096<br />

Non-sebaceous lymphadenoma of salivary glands: proposed<br />

development from intraparotid lymph nodes and risk of misdiagnosis<br />

C . Weiler1 , A . Agaimy2 , P . Zengel3 , J . Zenk4 , T . Kirchner1 , S . Ihrler5 1 2 Ludwig Maximilian University, Institute of Pathology, München, University<br />

Hospital Erlangen, Institute of Pathology, Erlangen, 3Ludwig Maximilian<br />

University, Head and Neck Surgery, München, 4University Hospital Erlangen,<br />

Head and Neck Surgery, 5Laboratory for Dermatohistology and Oral Pathology,<br />

München<br />

Aims. Non-sebaceous lymphadenoma (NSLA) is a rare benign salivary<br />

gland tumour composed of lymphoid and epithelial components. Definitionally,<br />

the epithelial component lacks sebaceous differentiation and,<br />

instead, displays a wide range of histological differentiation. In this study,<br />

we have collected 9 cases of NSLA to characterize their histological<br />

and immunohistochemical profile.<br />

Methods. The samples were histologically reviewed, and immunohistochemical<br />

stains for CK5/6, CK7, CK14, CK18, p63, and Ki67 performed.<br />

Patients were 6 males and 3 females (mean age, 50 years).<br />

Results. All tumours were located in the parotid gland and showed<br />

intimate intermingling of lymphoid tissue with islands or strands of<br />

epithelium with a wide spectrum of histological differentiation. The<br />

immunohistochemical profiles mirrored the epithelial differentiation;<br />

hence, areas with basaloid or lymphoepithelial differentiation strongly<br />

expressed CK5/6, CK14, and p63, while areas with ductal differentiation<br />

showed strong positivity for CK18/CK7 and CK5/6/CK14/p63 in luminal<br />

and basal cell layers, respectively. A hilus structure with salivary inclusions<br />

or D2-40 (podoplanin) positive marginal sinus were identifiable in 4<br />

and 9 of the cases, respectively, confirming origin within intra-/periparotid<br />

lymph nodes. Six cases were initially misdiagnosed as other benign<br />

(n=4) or malignant tumours (n=2).<br />

Conclusions. Our study on the largest series of NSLA reported to date<br />

provides strong evidence that NSLA belongs to the group of salivary<br />

gland tumours that pathogenetically develop from embryonic salivary<br />

gland inclusions in intra-/periparotid lymph nodes. Knowledge of the<br />

wide histological spectrum of this rare and presumably un<strong>der</strong>reported<br />

tumour is important in or<strong>der</strong> to avoid misdiagnosis, particularly as malignant<br />

tumour.<br />

Der Pathologe · Supplement 1 · 2012 |<br />

37

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!